Abstract
Background: Major depressive disorder (MDD) is associated with high mortality and morbidity rates, and currently, approximately 340 million people worldwide suffer from depression at some point in life. In view of the growing socio-economic and clinical impact, several studies have focused on the etiopathology of MDD, suggesting that not only the monoaminergic system but also other brain mechanisms may be involved in the pathophysiology of MDD. Recent studies have shown a link between inflammation and MDD and have also demonstrated that antidepressants and antiinflammatory drugs can act to reduce inflammation, thereby improving depressive symptoms. Animal models of depression are indispensable for studying the pathophysiology of this disorder and new treatments for it. Further, studies have shown that rodent models of depression are also associated with elevated levels of inflammation in the periphery and brain.
Objective: This review will highlight the role of immune inflammation in MDD and the significance of immune system modulators with antidepressant effects in the treatment of MDD, based on studies using animal models of depression.Keywords: Antidepressants, anti-inflammatory drugs, immune system, animal model of depression, major depressive disorder.
CNS & Neurological Disorders - Drug Targets
Title:Immune System Modulators with Antidepressant Effects: Evidence from Animal Models
Volume: 16 Issue: 4
Author(s): Helena M. Abelaira, Amanda L. Maciel, Joao Quevedo and Gislaine Z. Reus*
Affiliation:
- Laboratory of Neurosciences, University of Southern Santa Catarina, Criciúma, SC - 88806-000,Brazil
Keywords: Antidepressants, anti-inflammatory drugs, immune system, animal model of depression, major depressive disorder.
Abstract: Background: Major depressive disorder (MDD) is associated with high mortality and morbidity rates, and currently, approximately 340 million people worldwide suffer from depression at some point in life. In view of the growing socio-economic and clinical impact, several studies have focused on the etiopathology of MDD, suggesting that not only the monoaminergic system but also other brain mechanisms may be involved in the pathophysiology of MDD. Recent studies have shown a link between inflammation and MDD and have also demonstrated that antidepressants and antiinflammatory drugs can act to reduce inflammation, thereby improving depressive symptoms. Animal models of depression are indispensable for studying the pathophysiology of this disorder and new treatments for it. Further, studies have shown that rodent models of depression are also associated with elevated levels of inflammation in the periphery and brain.
Objective: This review will highlight the role of immune inflammation in MDD and the significance of immune system modulators with antidepressant effects in the treatment of MDD, based on studies using animal models of depression.Export Options
About this article
Cite this article as:
Abelaira M. Helena, Maciel L. Amanda, Quevedo Joao and Reus Z. Gislaine*, Immune System Modulators with Antidepressant Effects: Evidence from Animal Models, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170404141620
DOI https://dx.doi.org/10.2174/1871527316666170404141620 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease
Current Medicinal Chemistry Tolerability of Amine Uptake Inhibitors in Urologic Diseases
Current Drug Safety Message from the Editor-in-Chief
CNS & Neurological Disorders - Drug Targets Assessment and Imaging of the Cerebrovascular Glycocalyx
Current Neurovascular Research Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Oxidative Stress and Accelerated Aging in Neurodegenerative and Neuropsychiatric Disorder
Current Pharmaceutical Design Disorder in Milk Proteins: Structure, Functional Disorder, and Biocidal Potentials of Lactoperoxidase
Current Protein & Peptide Science Management of Side-Effects of Selective-Serotonin Re-Uptake Inhibitors in Children and Adolescents
Current Psychopharmacology Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
Current Topics in Medicinal Chemistry Carvedilol Promotes Retinal Ganglion Cell Survival Following Optic Nerve Injury via ASK1-p38 MAPK Pathway
CNS & Neurological Disorders - Drug Targets Brain Inflammation Following Intracerebral Hemorrhage
Current Neuropharmacology TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Cytoprotection by Melatonin, Precursors and Metabolites in an In Vitro Model of Neurotoxicity Induced by Okadaic Acid
Letters in Drug Design & Discovery Editorial [Hot Topic: Therapeutic Application of Melanocortin-4 Receptor Ligands (Guest Editor: John P. Mayer)]
Current Topics in Medicinal Chemistry Momordicacharantia: A New Strategic Vision to Improve the Therapy of Endoplasmic Reticulum Stress
Current Pharmaceutical Design Inhibitors of c-jun-N-Terminal Kinase (JNK)
Mini-Reviews in Medicinal Chemistry Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism